Accessibility

Accessibility builds on Camurus work to make its medicines available to as many patients in need as possible at prices that are sustainable for all parties. By taking a value-based healthcare approach which considers the value of the medicine to all aspects of society, Camurus encourages innovative and effective pricing mechanisms that aim to deliver treatment to more patients in need. This principle is particularly apparent in Camurus’ work with low income and low-medium income countries, and with vulnerable and low-income patient groups.

Access to treatment for more patients with opioid dependence

Camurus has developed a long-acting buprenorphine injection depot indicated for the treatment of opioid dependence – within a framework of medical, social and psychological treatment – which is currently approved in the EU, UK, Australia and several countries in the Middle East and North Africa. In 2023, the treatment was also approved in the US where it is licensed to Camurus’ partner Braeburn.

In the area of opioid dependence, Camurus works with healthcare providers and partners to expound the need for new treatment options. This has resulted in increased funding for and access to long-acting treatment in several countries, both in general care and the prison system.^2-5

Reinforcing and empowering healthcare systems

Camurus also works to improve the healthcare systems in which it operates. This includes working with governments, international health organizations, and non-governmental organizations to support and improve the quality of patient care. These efforts are focused on lowering the barriers to healthcare delivery and provision wherever patients exist. By contributing to making these health systems more robust, Camurus aims to ensure that patients’ access to its medicines is more reliable and sustainable for the long-term.

Increasing awareness, knowledge and reducing stigma

An important step to increase access to healthcare is to raise disease awareness and reduce potential stigma for those affected. Camurus supports and collaborates with healthcare and patient organizations to increase knowledge about serious and rare diseases. This work is conducted within the framework of the EFPIA (European Federation of Pharmaceutical Industries and Associations) guidelines. For more information on Camurus’ provision of grants and donations to healthcare and patient organizations, see Camurus’ transparency reporting 

Camurus conducts activities each year aimed at raising awareness and reducing stigma by supporting international campaigns, and in 2023 supported Rare Disease Day, Unite for Recovery, International Overdose Awareness Day, World Acromegaly Day and World NET Cancer Day. The company also supports initiatives focused on reducing stigma and improving access to treatment for women with opioid dependence – an underrepresented group in treatment programs. For example, in 2023 Camurus supported the campaign “A gateway within all women’s reach”, organized by the non-governmental, not-for-profit organization Dianova International, aimed at reducing stigma and improving women's access and adherence to addiction services.

Throughout the year, Camurus actively participates in leading international medical congresses to exchange knowledge and experiences with the aim of improving access and care for patients. The company also support several Investigator Sponsored Studies (ISS) – research projects run by external researchers with support from Camurus – aimed at strengthening the evidence base on opioid dependence and its treatment. Learn more about ISS and grants 

Developing new innovative medicines for diseases with high unmet medical need

Camurus has a broad and diversified pipeline with product candidates targeting diseases with high unmet medical needs, including cancer. For some, such as symptomatic polycystic liver disease, there is currently no approved pharmacological treatment available in the EU or US. 

In 2023, Camurus reported more than SEK 0.6 billion in research and development to bring forward new innovative treatments for diseases in the focus areas of central nervous system (CNS), rare diseases, oncology and supportive care.